I assure you, had I showed up, SFRX would have OBJECTED.

New Post Public Reply Private Reply Replies (1) Message Board
hedge_fun Coat Tail Rider #1526
I assure you, had I showed up, SFRX would have OBJECTED. The hearings are generally held in the Judge's chambers, or small rooms next to chambers. I should know, I showed up in Tampa before to face Huffman.

Now if/when the times comes and I need to go see Kyle and Craig, I'm more than happy to do it. I was invited by email by Craig to become a "co-defendant" in the case, but SFRX has NEVER filed anything with the Court that would/could make me one. I'm not sure that such a motion exist, but none-the-less, it was was Huffing and Puffing by SFRX.

Original Message
Subject: RE: What is it you want?
From: <craig@securuslawgroup.com>
Date: Thu, June 25, 2015 10:12 pm
To: <smallcapsmarket@gmail.com>
Cc: craig@securuslawgroup.com

Mr. SCM,

How would you like to be included as a defendant with Mr. Volentine for his upcoming trial on December 1, 2015 before Judge Foster. Since you post information SFRX website, under the name of "smallcapsmarket" and your postings are of great interest to the company since you have now confederated and joined with Mr. Volentine in his messages. Many of your postings are completely false and innacurate as his have been. He has not destructed himself to face a trial for damages by Seafarer for his already admitted falsities. Would you like to join as a co-conspirator. Mr. Volentine is on line for some multi-million in damages trial on December 1st. Do you want to join as a Defendant as a co-conspirator and libel party on Seafarer's behalf for your falsities as well. Come on in and join the party Pal. You will be surprised by our witnesses and evidence against you. They captured it all. Do not use Mr. Volentine as your front. He has enough problems.

Considering not that Judge Foster, but the Florida Bar found your claims unfounded and settled by Judge Foster, lets go a step further for what you are doing here by pairing with Volentine in Seafarer. Want to join now or do you want to be next in line. Up to you. We are monitoring all you do Sir. Either stop in untruths or be the next example for falsehoods.

Craig A. Huffman, Esquire
Securus Law Group, P.A.
13046 Racetrack Road #243
Tampa, Florida 33626
Phone: (888) 914-4144
Fax: (888) 783-4712
E-mail: Craig@securuslawgroup.com

from: craig@securuslawgroup.com
date: Thu, Jun 25, 2015 at 10:31 PM
to: <smallcapsmarket@gmail.com>
cc: craig@securuslawgroup.com
subject: Correction: What is it you want?

Sorry SCM,

That was Judge Isom who found you not to be credible as well as the Florida Bar. It was not Judge Foster. Sorry for confusion of who found you incredible. Judge Foster who is hearing the Volentine case for trial where we seek multi-millions in damages is separate, may be much more adept at your antics. Doubtful. But lets do that. Come on SCM, join the party with Volentine. Keep posting on this company and find out.

Craig A. Huffman, Esquire
Securus Law Group, P.A.
13046 Racetrack Road #243
Tampa, Florida 33626
Phone: (888) 914-4144
Fax: (888) 783-4712
E-mail: Craig@securuslawgroup.com

Well......I'm waiting.

Seafarer Exploration (SFRX) Stock Research Links

SFRX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

AEVEX Faces 48-Hour Deadline for Investor Class Action

Updated Category News Views 11

Clock Ticking on AEVEX Lawsuit Participation Ah, the twists and turns of the stock market! AEVEX Corp. (NYSE: AVEX) finds itself knee-deep in a class action lawsuit, and investors have a mere 48 hours left to make their stand as the lead plaintiff. This legal saga stems from the company's April 2026 IPO and spills into the muddy waters of securities law violations....

Continue Reading
Lundbeck's Board Leadership Transitions into New Era

Updated Category News Views 9

A Fresh Chapter for Lundbeck's Board Leadership Lundbeck is sparking some fresh boardroom energy, and it's not just business as usual. Dorothea Wenzel, who's been steering the ship, is stepping down come 2027—AGM in sight. Now, in swings Lars Fruergaard Jørgensen, ready to grab the wheel. Yeah, we've got some seasoned pharma muscles flexing here. The Before and After:...

Continue Reading
Faith and Resilience in China: The Legacy of the Long March

Updated Category News Views 14

History's got chapters that stick with you, and the Long March is one of those stories that shake you to your core. It all started one October evening in 1934, when more than 86,000 soldiers from the Red Army found themselves on the banks of the Yudu River. It was a scene straight out of a novel: 800-odd boats held together with coffin boards and timber beams, all set to...

Continue Reading
Antheia Secures $80M for Critical Medicine Onshoring

Updated Category News Views 20

Antheia's Bold Move to Onshore Medicine Production Folks, when it comes to pharmaceuticals, it's about time someone started serious about keeping things closer to home. Antheia just landed a huge $80 million conditional commitment from the U.S. Department of War's Office of Strategic Capital. The fine print? This isn't just about building business—it's a play to secure...

Continue Reading
Tomorrowland's Shanghai Return: An Electri-Lifesaver

Updated Category News Views 21

You know, every now and then, it's worth stepping out of the stock frenzy and diving into something as electrifying and far from the trading floor as Tomorrowland's latest Shanghai rendezvous. This ain't just any festival; it's the kind of hype that packs a punch—and frankly, it's a wild ride seeing such a spectacle set up shop in China, and sell out to boot. Partnering...

Continue Reading
ASTS Faces a Legal Countdown – Investors Take Note

Updated Category News Views 10

AST SpaceMobile's Legal Tangle AST SpaceMobile, Inc. (NASDAQ:ASTS) finds itself neck-deep in legal quagmire, with a class action lawsuit looming large. Investors who snapped up ASTS securities between March 4, 2025, and July 15, 2026, have until November 13, 2026, to reckon their grievances before the courts. This is no joke, folks. If you've lost dough because of shaky...

Continue Reading
UEG's New Advisory Board: Elevating Patient Voices

Updated Category News Views 19

Breaking Ground with Patient Representation Today's not-so-sunny forecast from Barcelona wasn't about the weather. United European Gastroenterology (UEG) rolled out its shiny new Patient Representatives Advisory Board (PRAB) during UEG Week 2026. This isn't just another committee on a never-ending list—it's a serious platform aimed at turning patient murmurs into a...

Continue Reading

Top 5 Most Recently Viewed Articles

Sera Prognostics to Showcase Innovations at RBC Healthcare Event

Updated Category News Views 112

Sera Prognostics to Showcase Innovations at RBC Healthcare Event Sera Prognostics Inc., known as The Pregnancy Company (NASDAQ: SERA), is focused on enhancing maternal and neonatal health through innovative pregnancy biomarker information. The company has recently announced its participation at an important healthcare event, highlighting its ongoing commitment to improve...

Continue Reading
Unlocking AI Potential: Insights from Netcracker CEO Andrew Feinberg

Updated Category News Views 268

Exciting Keynote at GITEX Global 2024 Netcracker Technology is buzzing with excitement as Andrew Feinberg, the Chairman and CEO, prepares for a pivotal keynote presentation at one of the largest tech events in the world, GITEX Global 2024. This annual technology conference draws innovators, industry leaders, and enthusiasts keen on understanding the future of technology....

Continue Reading
Adherium Empowers COPD and Asthma Management with iCARE Study

Updated Category News Views 147

Adherium's Transformative iCARE Study Results The innovative strides made by Adherium Limited (ASX:ADR) in respiratory health have shown promising outcomes as seen in the iCARE study. This study investigated the effectiveness of their Hailie® Smartinhaler® technology in improving adherence among patients suffering from chronic obstructive pulmonary disease (COPD) and...

Continue Reading
Medius Highlights Impending Finance Challenges Post AI Launch

Updated Category News Views 243

AI Fraud Concerns Elevate in the Finance Sector Medius has unveiled alarming findings indicating that nearly one in three finance professionals are unable to spot AI-generated fake receipts. This revelation surfaces amidst rising fears of fraud escalation following the recent launch of GPT-5.0. With the capabilities of AI continuously improving, finance teams must prepare...

Continue Reading
TD Cowen Sustainably Endorses Abbott Labs with Robust Price Target

Updated Category News Views 59

TD Cowen Affirms Buy Rating on Abbott Laboratories TD Cowen has reaffirmed its Buy rating on Abbott Laboratories (NYSE: ABT), maintaining a price target of $130.00 for the healthcare company's shares. This positive stance hinges on expectations that Abbott's upcoming third-quarter results will either meet or surpass current market predictions, allowing the company to...

Continue Reading